News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Brownstein Carrie
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/06/2023 |
4
| Brownstein Carrie (Chief Medical Officer) has filed a Form 4 on Zentalis Pharmaceuticals, Inc.|
Txns:
| Sold 8,906 shares
@ $19.4265, valued at
$173k
Sold 1,722 shares
@ $19.9102, valued at
$34.3k
|
|
| 10/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/31/2023 |
4
| Brownstein Carrie (Director) has filed a Form 4 on Shattuck Labs, Inc.|
Txns:
| Granted 40,258 options to buy
@ $2.72, valued at
$109.5k
|
|
| 02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/03/2022 |
4
| Brownstein Carrie (Chief Medical Officer) has filed a Form 4 on Zentalis Pharmaceuticals, Inc.|
Txns:
| Granted 100,000 shares
@ $0
Granted 300,000 options to buy
@ $22.21, valued at
$6.7M
Granted 100,000 options to buy
@ $22.21, valued at
$2.2M
|
|
| 10/03/2022 |
3
| Brownstein Carrie (Chief Medical Officer) has filed a Form 3 on Zentalis Pharmaceuticals, Inc. |
| 06/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/17/2021 |
4
| Brownstein Carrie (Director) has filed a Form 4 on Shattuck Labs, Inc.|
Txns:
| Granted 10,467 options to buy
@ $19.27, valued at
$201.7k
|
|
| 11/17/2021 |
3
| Brownstein Carrie (Director) has filed a Form 3 on Shattuck Labs, Inc. |
|
|